JAKARTA: A phase III, multicenter, randomized, double-blind, placebo-controlled, three-arm study of SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF with splenomegaly.
Animesh Dev Pardanani
No relevant relationships to disclose
Jorge E. Cortes
Research Funding - Sanofi
Francisco Cervantes
Consultant or Advisory Role - Novartis; Sanofi
Honoraria - Bristol-Myers Squibb; Novartis
Claire N Harrison
Consultant or Advisory Role - Celgene; Novartis; S*Bio; Sanofi ; YM BioSciences
Honoraria - Celgene; Novartis; S*Bio; Sanofi ; YM BioSciences
Research Funding - Novartis
Expert Testimony - S*Bio
Francesco Passamonti
Consultant or Advisory Role - Celgene; Novartis; Sanofi
Claudia Lebedinsky
Employment or Leadership Position - Sanofi
Frank Neumann
Employment or Leadership Position - Sanofi
Pamela Cohen
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Ayalew Tefferi
No relevant relationships to disclose